Details of the Drug

General Information of Drug (ID: DMT5ZK3)

Drug Name
AZD3355
Indication
Disease Entry ICD 11 Status REF
Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 140.07
Logarithm of the Partition Coefficient (xlogp) -1.4
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C3H8FNO2P+
IUPAC Name
[(2R)-3-amino-2-fluoropropyl]-hydroxy-oxophosphanium
Canonical SMILES
C([C@H](C[P+](=O)O)F)N
InChI
InChI=1S/C3H7FNO2P/c4-3(1-5)2-8(6)7/h3H,1-2,5H2/p+1/t3-/m1/s1
InChIKey
WVTGPBOMAQLPCP-GSVOUGTGSA-O
Cross-matching ID
PubChem CID
9833984
CAS Number
344413-67-8
DrugBank ID
DB11920
TTD ID
D03FFY

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gamma-aminobutyric acid B receptor (GABBR) TTDCVZW GABR1_HUMAN ; GABR2_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7705).
2 Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.Gut.2013 Sep;62(9):1248-55.